Intersect Capital’s Celgene Corp CELG Stock Holding History

Intersect Capital’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,777	Closed	-$262K	–	181
2019 Q1	$262K	Buy	+2,777	New	+$243K	0.11%	115
2018 Q4	–	Sell	-2,906	Closed	-$260K	–	138
2018 Q3	$260K	Hold	2,906	–	–	0.11%	109
2018 Q2	$231K	Buy	+2,906	New	+$241K	0.11%	113
2017 Q4	–	Sell	-1,637	Closed	-$239K	–	118
2017 Q3	$239K	Buy	1,637 +89	+6%	+$12.1K	0.14%	102
2017 Q2	$201K	Buy	+1,548	New	+$190K	0.12%	105
2016 Q3	–	Sell	-2,580	Closed	-$254K	–	115
2016 Q2	$254K	Sell	2,580 -38	-1%	-$3.93K	0.15%	93
2016 Q1	$262K	Buy	+2,618	New	+$270K	0.16%	91
2015 Q3	–	Sell	-1,937	Closed	-$224K	–	104
2015 Q2	$224K	Buy	1,937 +120	+7%	+$13.7K	0.19%	91
2015 Q1	$196K	Sell	1,817 -200	-10%	-$23.9K	0.15%	94
2014 Q4	$226K	Buy	+2,017	New	+$213K	0.19%	83

Other funds holding CELG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Intersect Capital's CELG Position: Q2 2019 in Review

Intersect Capital sold out of Celgene Corp (CELG) in Q2 2019, closing a stake of 2,777 shares — an estimated $262K sold.

Intersect Capital first reported a position in CELG in Q4 2014 and held it in 10 quarters. The position peaked at $262K in Q1 2019. 1,288 funds tracked by Wall St. Rank hold CELG as of Q2 2019.

Intersect Capital reported no remaining Celgene Corp position as of Q2 2019 after selling out during the quarter.
Intersect Capital sold 2,777 Celgene Corp shares in Q2 2019, an estimated $262K.
Intersect Capital first reported a position in Celgene Corp in Q4 2014 and held it in 10 quarters.
Intersect Capital's Celgene Corp position peaked at $262K in Q1 2019.
1,288 funds tracked by Wall St. Rank held Celgene Corp as of Q2 2019.

Based on Intersect Capital's 13F filing for Q2 2019, filed 9 Aug 2019.